R-Pharm: BaktoBlis (probiotic)

2022: Sachet Launch

On April 15, 2022, the R-Farm Group of Companies announced the expansion of the BaktoBLIS probiotic product line in Russia, designed to prevent oral and ENT infections and introduced into the Federal Clinical Recommendations of the Ministry of Health of the Russian Federation "Acute tonsillopharyngitis." In addition, the product is used in candidious stomatitis, for the prevention of acute otitis media, as well as for the restoration of the protective microflora of the oropharynx after therapy with antibiotics and antiseptics.

R-Pharm brings to the market BaktoBLIS powder in sachets, intended for small patients from 1.5 years old, as well as complex patients who are unable to resorb tablets. The developed form is enriched with vitamin D, which potentiates the effect of probiotic bacteria S. salivarus K12 - natural representatives of healthy myrcroflora - on immunity, which is extremely important in the season of respiratory infections.

In addition, in April 2022, an updated version of resorption tablets will be available, called BaktoBLIS +, which will completely replace the already familiar BaktoBLIS. The updated form contains 50mg less fructose and is also enriched with vitamin D.

We made every effort to make BaktoBLIS available to children under 3 years of age for the reason that we received many requests from both pediatricians and parents. We are convinced that the emergence of a new baby form of BaktoBLIS will improve the quality of life of even more small patients, because diseases such as candidiasis of the oral cavity or otitis media are still quite common among children under 3 years old, "said Olga Kutyrova, director of the R-Farm retail drugs department.